US Patent

US10781218 — Substituted inhibitors of menin-MLL and methods of use

Composition of Matter · Assigned to University of Michigan System · Expires 2037-03-15 · 11y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit the interaction between menin and certain proteins, and methods for treating diseases dependent on these proteins.

USPTO Abstract

The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Drugs covered by this patent

Patent Metadata

Patent number
US10781218
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-03-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.